Olema Oncology — Third Quarter 2026 Earnings Summary

Olema Oncology reported a net loss of $73.6 million for the third quarter of 2026, driven by increased clinical trial enrollment and preparation for potential commercialization. The company ended the quarter with $413.8 million in cash, cash equivalents, and marketable securities. Key operational milestones include continued strong enrollment in the Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136, with top-line data from the pivotal Phase 3 OPERA-01 trial anticipated in the first quarter of 2027. Additionally, Jason O'Byrne was appointed as Chief Financial Officer to support the company's expansion into a fully integrated oncology business.